MHRA approves first oral antiviral for COVID-19, molnupiravir (Lagevrio)
Molnupiravir works by interfering with the virus’ replication, keeping virus levels low and therefore reducing disease severity. It is approved for use in people who have mild to moderate COVID-19 and at least one risk factor for developing severe illness.
Source:
Medicines and Healthcare products Regulatory Agency
SPS commentary:
Summary of Product Characteristics and Patient Information Leaflet are available and the Public Assessment Report will be published shortly.